Abstract:Traumatic brain injury (TBI) is the leading cause of death and disability in young adults. Survivors of TBI frequently suffer from long‐term personality changes and deficits in cognitive and motor performance, urgently calling for novel pharmacological treatment options. To date, all clinical trials evaluating neuroprotective compounds have failed in demonstrating clinical efficacy in cohorts of severely injured TBI patients. The purpose of the present review is to describe the utility of animal models of TBI for preclinical evaluation of pharmacological compounds. No single animal model can adequately mimic all aspects of human TBI owing to the heterogeneity of clinical TBI. To successfully develop compounds for clinical TBI, a thorough evaluation in several TBI models and injury severities is crucial. Additionally, brain pharmacokinetics and the time window must be carefully evaluated. Although the search for a single‐compound, ‘silver bullet’ therapy is ongoing, a combination of drugs targeting various aspects of neuroprotection, neuroinflammation and regeneration may be needed. In summary, finding drugs and prove clinical efficacy in TBI is a major challenge ahead for the research community and the drug industry. For a successful translation of basic science knowledge to the clinic to occur we believe that a further refinement of animal models and functional outcome methods is important. In the clinical setting, improved patient classification, more homogenous patient cohorts in clinical trials, standardized treatment strategies, improved central nervous system drug delivery systems and monitoring of target drug levels and drug effects is warranted.LINKED ARTICLES This article is part of a themed issue on Translational Neuropharmacology. To view the other articles in this issue visit http://dx.doi.org/10.1111/bph.2011.164.issue‐4

Targets of Neuroprotection and Review of Pharmacological Interventions in Traumatic Brain Injury

Microglia: A Potential Drug Target for Traumatic Axonal Injury

The Potential of Stem Cells in Treatment of Traumatic Brain Injury

Animal modelling of traumatic brain injury in preclinical drug development: where do we go from here?

Traumatic brain injury: Symptoms to systems in the 21st century

'Comprehensive review of emerging drug targets in traumatic brain injury (TBI): challenges and future scope

The Rehabilitation Potential of Neurostimulation for Mild Traumatic Brain Injury in Animal and Human Studies

Brain-Derived Neurotrophic Factor and Nerve Growth Factor Therapeutics for Brain Injury: The Current Translational Challenges in Preclinical and Clinical Research

Neurostimulation for traumatic brain injury

Biomarkers and New Pharmacological Targets

Neuroprotective effects of nutraceuticals and natural products in Traumatic Brain Injury

Revisiting Traumatic Brain Injury: From Molecular Mechanisms to Therapeutic Interventions

Traumatic Brain Injury: Mechanistic Insight on Pathophysiology and Potential Therapeutic Targets

Non-pharmacological interventions for traumatic brain injury

Research progress on pleiotropic neuroprotective drugs for traumatic brain injury

Current understanding of neuroinflammation after traumatic brain injury and cell-based therapeutic opportunities

Beyond the Brain: Peripheral Interactions after Traumatic Brain Injury

Pediatric Traumatic Brain Injury: Models, Therapeutics, and Outcomes

Neurotrauma—From Injury to Repair: Clinical Perspectives, Cellular Mechanisms and Promoting Regeneration of the Injured Brain and Spinal Cord

Revisiting Excitotoxicity in Traumatic Brain Injury: From Bench to Bedside

Neurotrophins and neural stem cells in posttraumatic brain injury repair